Cargando…
Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study
BACKGROUND: More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually subjected to postoperative endocrine therapy (ET). Given that long-term ET can cause severe adverse effects it is important to determine the be...
Autores principales: | Niu, Nan, Zhang, Yinan, Bai, Yang, Wang, Xin, Yan, Shunchao, Song, Dong, Xu, Hong, Liu, Tong, Hua, Bin, Zhang, Yingchao, Liu, Jinchi, Qiao, Xinbo, Liu, Jiaxiang, Zheng, Xinyu, Cao, Hongyi, Liu, Caigang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901931/ https://www.ncbi.nlm.nih.gov/pubmed/36745010 http://dx.doi.org/10.7554/eLife.83045 |
Ejemplares similares
-
KCNJ15 deficiency promotes drug resistance via affecting the function of lysosomes
por: Qiao, Xinbo, et al.
Publicado: (2023) -
Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy
por: Giannakeas, Vasily, et al.
Publicado: (2018) -
Metastases after mastectomy for ductal carcinoma in situ of the male breast; A case report
por: Pant, Ved Prakash, et al.
Publicado: (2022) -
Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ
por: Anderson, Chelsea, et al.
Publicado: (2017) -
Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2(+)HR(+) breast cancer
por: Bu, Jiawen, et al.
Publicado: (2023)